Drug metabolism in vitro and in vivo results: How do these data support drug discovery?

Using Mass Spectrometry for Drug Metabolism Studies

Volumn , Issue , 2004, Pages 35-82

  Thompson, Thomas N ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056545610     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Ariens, E.J. and Simonis, A.M., Optimalization of pharmacokinetics —an essential aspect of drug development by ‘metabolic stabilization,” in Strategy in Drug Research, Keverling Buisman, J.A., Ed., Elsevier Scientific Publishing Company, Amsterdam, 1982, 165.
2. Testa, B. and Mayer, J.M., Drug metabolism and pharmacokinetics: implications for drug design, Acta. Pharm. Jugosl., 40, 315, 1990.
3. Humphrey, M.J. and Smith, D.A., Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectives, Xenobiotica, 22, 743, 1992.
4. Chiu, S-H.L., The use of in vitro metabolism studies in the understanding of new drugs, J. Pharmacol. Toxicol. Meth., 29, 77, 1993.
5. Smith, D.A., Design of drugs through a consideration of drug metabolism and pharmacokinetics, Eur. J. Drug Metab. Pharmacokin., 19, 193, 1994.
6. Smith, D.A., Jones, B.C., and Walker, D.K., Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics, Med. Res. Rev., 16, 243, 1996.
7. Lin, J.H. and Lu, A.Y.H., Role of pharmacokinetics and metabolism in drug discovery and development, Pharmacol. Rev., 49, 403, 1997.
8. Thompson, T.N., Early ADME in support of drug discovery: The role of metabolic stability studies, Curr. Drug Metab., 1, 215, 2000.
9. White, R.E., High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery, Annu. Rev. Pharmacol. Toxicol., 40, 133, 2000.
10. Navia, M.A. and Chaturvedi, P.R., Design principles for orally bioavailable drugs, Drug Discov. Today, 1, 179, 1996.
11. Thompson, T.N., Optimization of metabolic stability as a goal of modern drug design, Med. Res. Rev., 21, 412, 2001.
12. Chaturvedi, P.R., Decker, C.J., and Odinecs, A., Prediction of pharmacokinetic properties using experimental approaches during early drug discovery, Curr. Opin. Chem. Biol., 5, 452, 2001.
13. Riley, R.J., Martin, I.J., and Cooper, A.E., The influence of DMPK as an integrated partner in modern drug discovery, Curr. Drug Metab., 3, 527, 2002.
14. Roberts, S.A., Drug metabolism and pharmacokinetics in drug discovery, Curr. Opin. Drug Discov. Dev., 6, 66, 2003.
15. Roberts, S.A., High-throughput screening approaches for investigating drug metabolism and pharmacokinetics, Xenobiotica, 31, 557, 2001.
16. Ekins, S. et al. Present and future in vitro approaches for drug metabolism, J. Pharmacol. Toxicol. Meth., 44, 313, 2000.
17. Caldwell, G.W. et al. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery, Curr. Topics Med. Chem., 1, 353, 2001.
18. Bertrand, M., Jackson, P., and Walther, B., Rapid assessment of drug metabolism in the drug discovery process, Eur. J. Pharm. Sci., 11 (Suppl 2), S61, 2000.
19. Theil, F.P. et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection, Toxicol. Lett., 138, 29, 2003.
20. van de Waterbeemd, H., High-throughput and in silico techniques in drug metabolism and pharmacokinetics, Curr. Opin. Drug Discov. Dev., 5, 33, 2002.
21. Eddershaw, P.J. and Dickins, M., Advances in in vitro drug metabolism screening, Pharm. Sci. Tech. Today, 2, 13, 1999.
22. Bjornsson, T.D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PHRMA) perspective, Drug Metab. Disp., 31, 815, 2003.
23. Prentis, R.A, Lis, Y., and Walker, S.R., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies, Br. J. Clin. Pharmacol., 25, 387, 1988.
24. Cashman, J.R., Drug discovery and drug metabolism, Drug Discov. Today, 1, 209, 1996.
25. Peet, N.P., Selecting leads with pharmacokinetic data, Mod. Drug Discov., July/August, 21, 1999.
26. Rodrigues, A.D., Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective, Pharm. Res., 14, 1504, 1997.
27. Rodrigues, A.D., Rational high-throughput screening in preclinical drug metabolism, Med. Chem. Res., 8, 422, 1998.
28. Tarbit, M.H. and Berman, J., High-throughput approaches for evaluating absorption distribution, metabolism and excretion properties of lead compounds, Curr. Opin. Chem. Biol., 2, 411, 1998.
29. Wrighton, S.A., Ring, B.J., and Vandenbranden, M., The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies, Toxicol. Pathol, 23, 199, 1995.
30. Parkinson, A., An overview of current cytochrome P450 technology for assessing the safety and efficacy of new molecules, Toxicol. Pathol., 24, 45, 1996.
31. Smith, D.A. and Jones, B.C., Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes, Biochem. Pharmacol., 44, 2089, 1992.
32. Smith, D.A., Ackland, M.J., and Jones, B.C., Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics, Drug Discov. Today, 2, 406, 1997.
33. Smith, D.A., Ackland, M.J., and Jones, B.C., Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates, Drug Disccv. Today, 2, 479, 1997.
34. Pelkonen, O., Boobis, A.R., and Gundert-Remy, U., In vitro prediction of gastrointestinal absorption and bioavailability: an experts’ meeting report, Eur. J. Clin. Pharmacol., 57, 621, 2001.
35. Lipinski, C.A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev, 23, 3, 1997.
36. Kerns, E.H., High throughput physicochemical profiling for drug discovery, J. Pharm. Sci., 90, 1838, 2001.
37. Bergstrom, C.A. et al. Experimental and computational screening models for prediction of aqueous drug solubility, Pharm. Res., 19, 182, 2002.
38. Bevan, C. and Lloyd, R.S., A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates, Anal. Chem., 72, 1781, 2000.
39. Lombardo, F. et al. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds, J. Med. Chem., 44, 2490, 2001.
40. Tsuji, A. and Tamai, I. Carrier-mediated intestinal transport of drugs, Pharm. Res., 13, 963, 1996.
41. Stewart B.H. et al. Saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma, Pharm. Res., 10, 276, 1993.
42. Amidon, G.L., Merfeld, A.E., and Dressman, J.B., Concentration and pH dependency of a-methyldopa absorption in rat intestine, J. Pharm. Pharmacol., 38, 363, 1986.
43. Hu, M. and Borchardt, R.T., Mechanism of L-a-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2), Pharm. Res., 7, 1313, 1990.
44. 14C in rats, Chem. Pharm. Bull.,(Tokyo) 21, 2031, 1973.
45. Cercos-Fortea, T. et al. Influence of leucine on intestinal baclofen absorption as a model compound of neutral a-amino acids, Biopharm. Drug Dispos., 16, 563, 1995.
46. Thwaites, D.T. et al. D-cycloserine transport in human intestinal epithelial (Caco-2) cells mediated by a H-coupled amino acid transporter, Br. J. Pharmacol., 115, 761, 1995.
47. + coupled uphill transport of aminocephalosporins via the dipeptide transport system in rabbit intestinal brush-border membranes, J. Biol. Chem, 261, 14130, 1986.
48. Inui, K., Miyamoto, M., and Saito, H., Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: Specific transport systems in apical and basolateral membranes, J. Pharmacol. Exp. Therap., 261, 195, 1992.
49. Tamai, I. et al. Functional expression of intestinal depeptide/b-lactam antibiotic transporter in Xenopus laevis oocytes, Biochem. Pharmacol., 48, 881, 1994.
50. Tamai, I. et al. Functional expression of transporter for b-lactam antibiotics and dipeptides in Xenopus laevis oocytes injected with messenger RNA from human, rat and rabbit small intestines, J. Pharmacol. Exp. Therap., 273, 26, 1995.
51. Boll, M. et al. Expression cloning of a cDNA from rabbit small intestine related to proton-coupled transport of peptides, b-lactam antibiotics and ACE-inhibitors, Pflugers-Arch., 429, 146, 1994.
52. Amidon, G.L. and Lee, H.J., Absorption of peptide and peptidomimetic drugs, Annu. Rev. Pharmcol. Toxicol., 34, 321, 1994.
53. Yee, S. and Amidon, G.L., Oral absorption of angiotensin-converting enzyme inhibitors and peptide prodrugs’ in Peptide-based Drug Design, Taylor, M.D and Amidon, G.L, Eds., American Chemical Society, Washington, D.C., 1995, 299.
54. Kramer, W. et al. Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and b-lactam antibiotics, Biochim. Biophys. Acta, 1027, 25, 1990.
55. Hashimoto, N. et al. Renin inhibitor: transport mechanism in rat small intestinal brush-border membrane vesicles, Pharm. Res., 11, 1448, 1994.
56. Takano, M. et al. Bestatine transport in rabbit intestinal brush-border membrane vesicles, Biochem. Pharmacol., 47, 1089, 1994.
57. Walter, E. et al. Transepithelial properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data, Pharm. Res., 12, 360, 1995.
58. Mizuma T. et al. Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs, Biochem. Pharmcol., 43, 2037, 1992.
59. Osiecka, I. et al. In vitro drug absorption models. I. Brush border membrane vesicles, isolated mucosal cells and everted intestinal rings: Characterization and salicylate accumulation, Pharm. Res., 2, 284, 1985.
60. Takanaga, H., Tamai, I., and Tsuji, A., pH-Dependent and carrier-mediated transport of salicylic acid across Caco-2 cells, J. Pharm. Pharmacol., 46, 567, 1994.
61. Tsuji, A. et al. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism, Pharm. Res., 11, 30, 1994.
62. Tamai, I. et al. Proton-cotransport of pravastatin across intestinal brush-border membrane, Pharm. Res., 12, 1727, 1995.
63. + and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane, Biochem. Pharmacol., 38, 1019, 1989.
64. Swaan, P.W. and Tukker J.J., Carrier-mediated transport mechanism of foscarnet (trisodium phosphonoformate hexahydrate) in rat intestinal tissue, J. Pharmacol. Exp. Therap., 272, 242, 1994.
65. Kim R.B., Transporters and xenobiotic disposition, Toxicology, 181-182, 291, 2002.
66. Kim, R.B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res., 16, 408, 1999.
67. Cvetkovic, M. et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866, 1999.
68. Fromm, M.F. et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine, Circulation, 99, 552, 1999.
69. Kim, R.B. et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 1998.
70. Polli, J.W. et al. Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Therap., 299, 620, 2001.
71. Kansy, M., Senner, F., and Gubernator, K., Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes, J. Med. Chem., 41, 1007, 1998.
72. Audus K.L. et al. The use of cultured epithelial and endothelial cells for drug transport and metabolism studies, Pharm. Res., 7, 435, 1990.
73. Artursson, P. and Karlsson, J., Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells, Biochem. Biophys. Res. Comm., 175, 880, 1991.
74. Irvine, J.D. et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening, J. Pharm. Sci., 88, 28, 1999.
75. Rane, A., Wilkinson, G.R., and Shand, D.G., Prediction of hepatic extraction ratio from in vitro measurements of intrinsic clearance, J. Pharmacol. Exp. Therap., 200, 420, 1977.
76. Houston, J.B., Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance, Biochem. Pharmacol., 47, 1469, 1994.
77. Houston, J.B. and Carlile, D.J., Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices, Drug Metab. Rev., 29, 891, 1997.
78. Ito, K. et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport, Annu. Rev. Pharmacol. Toxicol., 38, 461, 1998.
79. Iwatsubo, T. et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data, Pharmacol. Therap., 73, 147, 1997.
80. Lave, T. et al. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans, Clin. Pharmacokinet., 36, 211, 1999.
81. Obach R.S. et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data, J. Pharmacol. Exp. Therap., 283, 46, 1997.
82. Guengerich, F.P. and Macdonald, T.L., Mechanisms of cytochrome P450 catalysis, FASEB J, 4, 2453, 1990.
83. Halliday, R.C. et al. Synthetic strategies to lower affinity for CYP2D6, Eur. J. Drug Metab. Pharmacokin., 22, 291, 1997.
84. de Groot, M.J. et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6, J. Med. Chem, 42, 1515, 1999.
85. de Groot, M.J. et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6, J. Med. Chem., 42, 4062, 1999.
86. Ekins, S. et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-4503A4 inhibitors, J. Pharmacol. Exp. Therap., 290, 429, 1999.
87. Ekins, S. et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates, J. Pharmacol. Exp. Therap., 291, 424, 1999.
88. Jones, B.C. et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase), Drug Metab. Disp., 24, 260, 1996.
89. Ekins, S. et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6, J. Pharmacol. Exp. Therap., 288, 21, 1999.
90. Lewis, D.F.V. et al. Molecular modeling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4, Xenobiotica, 29, 361, 1999.
91. Huang, T.L. et al. Hydrolysis of carbonates, thiocarbonates, carbamates, and carboxylic esters of a-naphthol, b-naphthol, and p-nitrophenol by human, rat, and mouse liver carboxylesterases, Pharm. Res., 10, 639, 1993.
92. Parkinson, A., Biotransformation of xenobiotics, in Casserett and Doull’s Toxicology, 5th edition, Klaassen, C.D., Ed., McGraw Hill, New York, 1996, 113.
93. Ackerman, B.L. et al. Increasing the throughput of microsomal stability screening using fast gradient elution LC/MS. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, May 31-June 4, 1998.
94. Ho, J. et al. A strategy for achieving higher throughput in screening for metabolic stability, Abstracts of the 1999 annual meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November, 1999.
95. Korfmacher, W.A. et al. Development of an automated mass spectrometry system for the quantitative analysis of liver microsomal incubation samples: a tool for rapid screening of new compounds for metabolic stability, Rapid Commun. Mass Spectrom., 13, 901, 1999.
96. Ayrton, A. and Morgan, P., Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 2001.
97. Eckhardt, U. et al. First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver, Biochem. Pharmocol., 52, 85, 1996.
98. Cvetkovic, M. et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866, 1999.
99. Morgan, P. et al. Identification of OATP-mediated uptake of a series of lipophilic bases, Abstracts of the 9th North American ISSX meeting, Nashville, TN, October 25-29, 1999.
100. van Montfoort, J.E. et al. Polyspecific organic anion transporting polypeptidss mediate hepatic uptake of amphipathic type H organic cations, J. Pharmacol. Exp. Therap, 291, 147, 1999.
101. Hsiang, B. et al. A novel human hepatic organic anion transporting polypeptide (OATP2), J. Biol. Chem, 274, 37161, 1999.
102. Konig, J. et al. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem., 275, 23161, 2000.
103. Nagel, G. et al. A reevaluation of substrate specificity of the rat cation transporter rOCT1, J. Biol. Chem., 272, 31953, 1997.
104. Zhang, L., Schaner, M.E., and Giacomini, K.M., Functional characterization of an organic transporter (hOCT1) in a transiently transfected human cell line, J. Pharmacol. Exp. Therap., 286, 354, 1998.
105. Kim, R.B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res., 16, 408, 1999.
106. Fromm, M.F. et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine, Circulation, 99, 552, 1999.
107. Kim, R.B. et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 1998.
108. Sasabe, H., Tsuji, A., and Sugiyama, Y., Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats, J. Pharmacol. Exp. Therap., 284, 1033, 1998.
109. Yamazaki, M. et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathways mediated by the canalicular multispecific organic anion transporter, Drug Metab. Disp., 25, 1123, 1997.
110. Sathirakul, K. et al. Multiple transporter systems for organic anions across the bile canalicular membrane, J. Pharmacol. Exp. Therap., 284, 1033, 1994.
111. Hooijberg, J.H. et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2, Cancer Res., 59, 2532, 1999.
112. Chu, X.Y., Kato, Y., and Sugiyama, Y., Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rat, Cancer Res., 57, 1934, 1997.
113. Ishizuka, H. et al. Temocaprilat, a novel antiotensin-converting enzyme inhibitor, is exrected in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR), J. Pharmacol. Exp. Therap, 280, 1304, 1997.
114. Liu, X. et al. Correlation of biliary excretion in sandwich cultured rat hepatocytes and in vivo in rats, Drug Metab. Dispos., 27, 637, 1999.
115. LeCluyse, E.L., Audus, K.L., and Hochman, J.H., Formation of extensive canalicular networks by rat hepatocytes cultured in collagen/sandwich configuration, Am. J. Physiol., 266, 1764, 1994.
116. Ishizuka, H., et al. Species differences in the transport activity for organic anions across the bile canalicular membrane, J. Pharmacol. Exp. Therap., 290, 1324, 1999.
117. Lin J.H., Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics, Drug Metab. Disp., 26, 1202, 1998.
118. Gumbleton, M. and Audus, K.L., Progress and limitation in the use of in vitro cell cultures to serve as permeability screens for the blood brain barrier, J. Pharm. Sci., 90, 1681, 2001.
119. Kariv, I., Cao, H., and Oldenburg, K.R., Development of a high throughput equilibrium dialysis method, J. Pharm. Sci., 90, 580, 2001.
120. Banker, M.J., Clark, T.H., and Williams, J.A., Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding, J. Pharm. Sci., 92, 967, 2003.
121. Wring, S.A. et al. Automated plasma protein binding screen: rapid, robust and timely for drug discovery, Abstracts of the 10th North American ISSX meeting, Indianapolis, IN, October, 2000, #85.
122. Gu, C. et al. Assays of ligand-human serum albumin binding using pulsed ultrafiltration and liquid chromatography-mass spectrometry, Combi. Chem. High Thr. Scr, 2, 353, 1999.
123. Parikh, H.H. et al. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening, Pharm. Res., 17, 632, 2000.
124. Lin, J.H., Species similarities and differences in pharmacokinetics, Drug Metab. Disp, 23, 1008, 1995.
125. Lombardo, F. et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data, J. Med. Chem., 45, 2867, 2002.
126. Oie, S. and Tozer, T.N., Effect of altered plasma protein binding on apparent volume of distribution, J. Pharm. Sci., 68, 1203, 1979.
127. Doan, K.M.H. et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs, J. Pharmacol. Exp. Ther., 303, 1029, 2002.
128. van de Waterbeemd, H. et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors, J. Drug Targeting, 6, 151, 1998.
129. Lee, G. et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations, Pharmacol. Rev., 53, 569, 2001.
130. Clark, D.E., Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood brain barrier penetration, J. Pharm. Sci., 88, 815, 1999.
131. Gratton, J.A. et al. Molecular factors influencing drug transfer across the blood-brain barrier, J. Pharm. Pharmacol., 49, 1211, 1997.
132. Audus, K.L. and Borchardt, R.T., Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism, Pharm. Res., 3, 81, 1986.
133. Otis, K.W. et al. Evaluation of the BBMEC model for screening the CNS permeability of drugs, J. Pharmacol. Toxicol. Method, 45, 71, 2001.
134. Janusz, M.J. et al. Pharmacological evaluation of selected, orally active peptidyl inhibitors of human neutrophil elastase, J. Pharmacol. Exp. Therap., 275, 1233, 1995.
135. Thompson, T.N. et al. Selection of an elastase inhibitor with improved bioavailability from a series of structurally related analogs. Abstracts of the 4th International ISSX meeting, Seattle, WA, August, 1995, #315.
136. Burkholder, T.P. et al. Chemical synthesis and structure activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists, Bioorg. Med. Chem. Lett., 7, 2531, 1997.
137. Stratford, R.E. et al. Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication, J. Pharm. Sci., 88, 747, 1999.
138. Mandagere, A.K., Thompson, T.N., and Hwang, K-K., A graphical method for estimating oral bioavailability of drugs in humans and other species from their caco-2 permeability and in vitro liver enzyme metabolic stability rates, J. Med. Chem, 45, 304, 2002.
139. Smith, D., Schmid, E., and Jones, B. Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?, Clin. Pharmacokin., 41, 1005, 2002.
140. Lipinski, CA., Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Meth., 44, 235, 2000.